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Abstract
Purpose The purpose of this study is to elicit the role of
oral low-dose sirolimus as a corticosteriod-sparing agent for
active uveitis.
Methods A retrospective, interventional case series was
performed by reviewing the clinical records of all patients
treatedwithoral,low-dosesirolimus(1–4mgdaily)forsevere
uveitis. Data reviewed included symptomatic improvement,
Snellen best-corrected visual acuity, corticosteroid require-
ment, sirolimus levels, intraocular inflammation, spectral-
domain optical coherence tomography, and fluorescein
angiogram. Primary outcome measures were determined by
the ability to decrease the intraocular inflammation, cortico-
steroid requirement, and frequency of flares.
Results Eight patients with varied diagnoses were treated
with oral low-dose sirolimus for severe, chronic uveitis
between 2008 and 2010. In four of the eight patients, there
was an improvement of all primary outcome measures.
While sirolimus monotherapy was successful in only one
patient, a sirolimus/methotrexate combination was success-
ful in three patients. Although there was a good initial
response in three patients, treatment was a failure after
serious side effects forced the cessation of sirolimus
therapy. One patient was lost to follow-up.
Conclusion Sirolimus may have a limited role in severe
uveitis as an adjunct corticosteroid-sparing agent in
combination with more standard immunosuppressive
agents. Oral low-dose sirolimus appeared to be better
tolerated than higher doses, but there were a significant
number of adverse events, requiring therapy to be stopped.
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Introduction
Uveitis results from a wide variety of infectious and non-
infectious insults, and it often presents a difficult challenge
in terms of etiology and treatment. It is estimated that more
than 280,000 people in the US are affected by uveitis each
year, and it is responsible for up to 10% of all cases of
blindness [1]. Patients can become unresponsive or refrac-
tory to topical or oral corticosteroid therapy, requiring other
classes of immunomodulatory drugs during the course of
their treatment. Methotrexate, cyclosporine, azathioprine,
and mycophenolate mofetil are the more common
corticosteroid-sparing agents currently used to treat uveitis;
however, these agents are limited by a narrow therapeutic
window and have significant side effects that often
modulate their use.
Sirolimus, also known as rapamycin, inhibits antigen-
induced proliferations of T cells and B cells and antibody
production by inhibiting mTOR, a key regulatory enzyme
required for proliferation and differentiation [2]. Sirolimus
forms a complex with the intracellular protein FKBP12,
which blocks the activation of the cell cycle kinase mTOR,
inhibiting the multifunctional serine–threonine kinase,
resulting in the blockage of progression at the juncture of
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has a broad spectrum of activity that has demonstrated the
ability to inhibit inflammation, proliferation, angiogenesis,
fibrosis, and hyperpermeability. Sirolimus currently has
multiple uses in the prevention of rejection in organ
transplantation and, recently, in the treatment of advanced
renal cell carcinoma [5]. Sirolimus-eluting cardiac stents
have been shown to limit the rate of overgrowth of tissue
and thus prevent coronary restenosis [6]. Early studies
suggest that it may be an effective agent for controlling
severe uveitis and that it may also have a role in treating age-
related macular degeneration [7].
Methods
A retrospective chart review of all electronic medical
records of patients treated with sirolimus for severe
uveitis at the Walter Reed Army Medical Center
Ophthalmology Service was completed. The purpose of
this study was to elicit the role of low-dose oral
sirolimus as a corticosteriod-sparing agent in the treat-
ment of active uveitis. Permission was granted by the
Institutional Review Board for this research, and this
research adhered to the tenets of the Declaration of
Helsinki. All patients had previously had an extensive
workup to include laboratory examination, radiologic
studies, and biopsy, if necessary. The etiology of the
disease was varied, and they are listed in Table 1.
A thorough risk–benefit analysis and discussion of
immunomodulatory agents and corticosteriod therapy were
had with each patient. Every patient started on sirolimus
chose it over a more standard regimen. Patients were started
on sirolimus 1–4 mg po daily. Sirolimus blood levels were
drawn serially, and sirolimus was titrated to 4–12 ng/mL.
For most indications, the target serum blood level of
sirolimus is 10–20 μg/mL. Both experimental animal and
clinical data suggest that adverse events and their associated
severity are correlated with blood concentrations [2].
Therefore, low-dose oral sirolimus with a target serum
blood level of 4–12 μg/mL should be better tolerated.
Patients were monitored regularly to determine effective-
ness of the therapy and side effect profiles. Data reviewed
included symptomatic improvement, Snellen best-corrected
visual acuity, corticosteroid requirement, sirolimus levels,
intraocular inflammation determined with slit lamp exam-
ination and binocular indirect ophthalmoscopy using
standardization of uveitis nomenclature criteria [8], Cirrus
spectral-domain optical coherence tomography, and fluo-
rescein angiograms. Primary outcome measures were
determined by the ability to decrease the intraocular
inflammation, corticosteroid requirement, and frequency
of flares.
Results
Eight patients were treated with oral low-dose sirolimus for
active uveitis between 2008 and 2010. The patients'
demographics, clinical details, and previous treatments are
listed in Table 1. Three patients had a diagnosis of
sarcoidosis, two patients had idiopathic uveitis, one patient
had sympathetic ophthalmia, one patient had HLA-B27
associated panuveitis, and one patient had intermediate
uveitis secondary to Lyme disease. There were six males
and two females. The ages ranged from 21 to 79 with a
mean age of 47. Seven of eight patients were previously
treated with systemic corticosteroids to control their disease
at the initiation of oral, low-dose sirolimus. One patient was
started on sirolimus as a first-line agent. Three patients had
previously been treated with a subtenons injection of
triamcinolone. One patient had been previously treated
with a corticosteroid-sparing agent, and one was treated
with intravenous methylprednisolone.
The clinical outcomes are listed in Tables 2 and 3.I n
four of the eight patients, oral low-dose sirolimus was
considered a success. The duration of treatment ranged
from 21 to 65 weeks, with a mean duration of 44.5 weeks.
Patient 1 had an improvement of all primary outcome
measures with oral low-dose sirolimus monotherapy. In
contrast, patients 2–4 had improvements of all primary
outcome measures with a combination of oral low-dose
sirolimus and methotrexate. In patients 2 and 3, methotrex-
ate was added to the sirolimus regimen after a flare. Patient
3 had previously failed methotrexate therapy. In patient 4,
oral low-dose sirolimus was added to the methotrexate
regimen after a flare.
Treatment was considered a failure in three patients after
serious side effects forced the cessation of sirolimus. Patient
5 was found to have a left popliteal deep vein thrombosis
during week 8 of sirolimus. It was later discovered that the
patient smoked more significantly than initially reported
(one pack per day). Patient 6 developed mental status
changes due to a recurrence of aseptic meningitis during
week 6 of sirolimus. The patient had a history of hepatitis B
and one previous episode of aseptic meningitis. The patient
recovered with no sequelae. Patient 7 developed thrombo-
cytopenia during week 4 of sirolimus. Her platelet count
dropped from 160,000 to 80,000 and rebounded after
cessation. However, patients 5 and 6 did have a good
initial response to oral low-dose sirolimus therapy. Patient
8 was lost to follow-up.
Discussion
Sirolimus is a unique and potent agent with broad anti-
inflammatory and immunomodulatory activities. Early
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including treating patients with retinal thickening secondary
to leakage as in neovascular age-related macular degener-
ation and diabetic macular edema [9]. Sirolimus inhibits the
translation and activity of hypoxia-inducible factor-1 alpha
(HIF-1a), a stress-activated protein that is a potent
stimulator of vascular endothelial growth factor (VEGF),
and its inhibition affects VEGF both upstream at the
production level and downstream at the receptor level
[10]. This inhibition is a direct effect on the endothelial
barrier, independent of vasodilation, and plays an important
role in angiogenesis and hyperpermeability [11]. A study
showed that sirolimus was superior to VEGF inhibition in a
co-culture assay of endothelial cells (EC) and retinal
pigment epithelium (RPE) by reducing EC sprouting in
groups that did not respond to anti-VEGF treatment and by
reducing both VEGF production in RPE and the respon-
siveness of EC to stimulation [12]. Sirolimus might
therefore be a therapeutic option for choroidal neovascula-
rization (NSV) patients that do not respond sufficiently to
the established anti-VEGF treatments or may be an
excellent combination agent, improving overall outcomes
and the intervals between anti-VEGF injections. Sirolimus
also has broad inhibitory effects of many inflammatory
factors that are not currently addressed in treatment relevant
to the development of geographic atrophy, such as fibrosis,
leading to irreversible photoreceptor death. It was also
reported that, following the administrationofsirolimus,there
wasareductionofthetumorburdeninLHBETATAG transgenic
retinoblastoma tumors [Murray TG, Piña Y, Houston S, et al.
Retinoblastoma Tumor Burden Control: Periocular mTOR
Inhibitor Rapamycin Decreases Tumor Burden in Advanced
LHBETATAG Murine Retinoblastoma. Presented at: Annual
Meeting of Association for Research in Vision and Oph-
thalmology (ARVO); May 2010; Fort Lauderdale, Fla].
The role of sirolimus in treating patients with severe
uveitis is evolving. Early studies suggest sirolimus may be
an effective agent for controlling uveitis, but its role was
not clearly defined [Wroblewski KJ, Sen HN, Yeh S, it al.
Combination Daclizumab and Sirolimus Therapy for the
Induction of Immune Tolerance in Non-Infectious Interme-
diate and Posterior Uveitis. Paper presented at: ARVO;
May 2009; Fort Lauderdale, Fla]. Two experimental studies
using animal models suggested a synergistic therapeutic
effect of combination therapy with low doses of calcineurin
inhibitors cyclosporine and tacrolimus [13]. A study of
human patients with refractory uveitis, limited to patients
whose disease was not controlled with at least two or more
separate steroid immunosuppressants, showed sirolimus
therapy was effective in five of eight patients [14].
Table 1 Patient's demographics, clinical details, and previous treatments
Case Age Sex History Diagnosis Previous therapy Reason for sirolimus
1 67 M Panuveitis OU with CME OD>
OS treated with topical steroids.
Sarcoidosis Topical ketorolac,
topical prednisolone
Patient wanted to avoid
oral prednisone
2 39 M Bilateral recurrent anterior uveitis
and scleritis treated with multiple
orbital floor steroid injections.
Sarcoidosis Subtenon triamcinolone,
oral prednisone
Frequent flares
3 31 F Chronic anterior uveitis with CME
OD previously treated with prednisone
and methotrexate. Poor control of
inflammation with frequent flares.
Idiopathic Subtenon triamcinolone,
oral prednisone, oral
methotrexate
Uncontrolled inflammation
with previous regimen
4 26 M Bilateral chronic intermediate uveitis.
Treated for Lyme disease by
infectious diseases.
Secondary to Lyme
disease
Oral prednisone, oral
methotrexate
Uncontrolled inflammation
with previous regimen
5 54 M Granulomatous anterior uveitis with
vasculitis and choroidal infiltrates
OD s/p repair of ruptured globe
and eventual enucleation OS.
Sympathetic
ophthalmia
IV methylprednisolone,
oral prednisone
Uncontrolled inflammation
despite maximal dose of
oral prednisone
6 61 M Panuveitis OU treated with orbital floor
steroid injections and high-dose oral
corticosteroids. History of hepatitis
C and aseptic meningitis.
Sarcoidosis Subtenon triamcinolone,
oral prednisone
Avoid higher doses of oral
prednisone
7 79 F Panuveitis with CME OD>OS treated
with oral corticosteroids. History of
chronic anemia.
Idiopathic Oral prednisone Avoid higher doses of oral
prednisone
8 21 M Recurrent panuveitis treated with high
doses of oral corticosteroids.
HLA B27
positive
Oral prednisone Uncontrolled inflammation
despite maximal dose of
oral prednisone
F female, M male
J Ophthal Inflamm Infect (2011) 1:29–34 31Table 2 Clinical outcomes
Case Pre-sirolimus
BCVA
Post-sirolimus
BCVA
Clinical course Corticosteroid
requirement
Clinical outcome Current therapy
1O D –20/50 OD–20/25 Resolution with sirolimus
2 mg/day
Did not require
prednisone
Decreased inflammation Sirolimus 2 mg/day
OS–20/25 OS–20/20 Decreased flare rate
2O D –20/30 OD–20/15 Initial improvement
with a flare 5 weeks
after starting sirolimus
40 to 5 mg/day with
sirolimus/MTX
combination
Decreased inflammation Sirolimus 3 mg/day
OS–20/30 OS–20/20 No additional flares after
adding MTX
Decreased flare rate MTX 20 mg/week
Prednisone 5 mg/day
3O D –20/150 OD–20/25 No initial improvement
with sirolimus 2 mg/day
40 to 5 mg/day with
sirolimus/MTX
combination.
Decreased inflammation,
decreased flare rate
Sirolimus 4 mg/day
Increased to 4 mg/day and
restarted MTX 10 mg/
week with resolution
of CME
MTX 10 mg/week
Prednisone 5 mg/day
4O D –20/25 OD–20/20 Improvement with the
addition of sirolimus
3 mg/day to MTX
25 mg/week
10 mg/day to tapered off Decreased inflammation Sirolimus 3 mg/day
OS–20/25 OS–20/20 Decreased flare rate MTX 25 mg/week
5O D –20/20 OD–20/15 Improvement with
sirolimus 3 mg/day
and cyclosporine
50 mg BID
20 to 10 mg/day while
on sirolimus
Failure due to side effects Cyclosporine 100 mg
BID
Sirolimus was stopped
after the patient
developed a DVT
Prednisone 20 mg/day
6O D –20/30 OD–20/25 Initial improvement of
vision but sirolimus
was stopped due to a
recurrence of aseptic
meningitis
Not enough data Failure due to side effects Prednisone 20 mg/day
OS–20/30 OS–20/20
7O D –20/60 No data Platelet count dropped
from 160,000 to 80,000
after starting sirolimus
Not enough data Failure due to side effects Prednisone 20 mg/day
OS–20/50 Sirolimus was stopped
and the platelets
rebounded
8O D –20/150 No data Missed several follow-up
appointments
No data Lost to follow-up No data
OS–10/100
MTX methotrexate; BCVA best corrected visual acuity; CME cystoid macular edema
Table 3 Duration of sirolimus therapy and dosage
Case Duration of therapy
(weeks)
Initial dose
(mg)
Final dose
(mg)
Weight
(kg)
Number of
flares
Still taking Side effects
1 65 2 2 95 0 Yes No significant side effects to date
2 50 3 4 122 1 Yes No significant side effects to date
3 42 2 4 86 1 Yes No significant side effects to date
4 21 3 3 102 0 Yes No significant side effects to date
5 8 2 3 79 1 No DVT-left popliteal
6 6 2 2 72 0 No Nausea, vomiting, recurrence of aseptic
meningitis
7 4 2 2 64 0 No Thrombocytopenia
8 2 2 2 80 No data No No data
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intolerable side effects or failure to control uveitis.
Maximum doses ranged from 4 to 12 mg/day, with blood
levels of up to 25 ng/mL. Researchers found that higher
blood levels led to an increased side effect profile, mostly
dermatological and gastrointestinal in nature, with little
additional benefits.
In our series, three out of seven patients stopped taking
sirolimus due to a serious side effect. However, two of
those patients had significant confounding factors. The
other four patients tolerated the medication well with little
to no side effects. This could be explained by the relatively
low doses of sirolimus used in comparison to the previous
study. As a solo immunosuppressive agent, our limited
study suggests that oral low-dose sirolimus has little role in
the treatment of active uveitis. However, oral low-dose
sirolimus used in combination with methotrexate worked
well for three patients in this series. Commonly described
side effects include anemia, thrombocytopenia, hypercho-
lesterolemia, arthralgias, and gastrointestinal problems.
Sirolimus has also been shown to be associated with Bk
virus-associated nephropathy, although at the lower end of
the range described with various other contemporaneous
immunosuppressive regimens [15].
Since oralor intravenous administrationpresentsthe issues
of systemic immunosuppression and side effects, investiga-
tors have been evaluating the safety, tolerability, and
biological activity of sirolimus when delivered by either a
subconjunctival or intravitreal injection, making systemic
exposure negligible. Animal studies have shown that there is
no retinal toxicity with intravitreal sirolimus injections [16,
17]. It was recently suggested that retinal and choroidal
sirolimus levels are sustained longer, following subconjunc-
tival injection, as the sclera acts as a reservoir for the highly
lipophilic drug [Nivaggioli T, Bao JX, Farooq S, et al.
Pharmacokinetics of a locally administered subconjunctival
ocular formulation of sirolimus in rabbits and humans. Paper
presented at: ARVO; May 2009; Fort Lauderdale, Fla].
There were no dose-limiting toxicities, ocular inflammation,
or increase in intraocular pressure.
Conclusion
Oral low-dose sirolimus appears to have a limited role in
active uveitis as an adjunct corticosteroid-sparing agent in
combination with more standard immunosuppressive
agents. Oral low-dose sirolimus appeared to be better
tolerated than higher doses, but there were a significant
number of adverse events, requiring therapy to be stopped.
The study suffers from limited numbers and a selection
bias. Sirolimus should only be used after proper patient
selection with an extensive risk–benefit analysis and a
thorough discussion with the patient. Patients taking sirolimus
need close monitoring, including necessary lab work such as
blood levels, CBCs, liver function tests (LFT), and lipid levels.
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